These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

682 related articles for article (PubMed ID: 28969604)

  • 1. Pathogenic role of glycan-specific IgG antibodies in IgA nephropathy.
    Zhao YF; Zhu L; Liu LJ; Shi SF; Lv JC; Zhang H
    BMC Nephrol; 2017 Sep; 18(1):301. PubMed ID: 28969604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mesangial cells from patients with IgA nephropathy have increased susceptibility to galactose-deficient IgA1.
    Ebefors K; Liu P; Lassén E; Elvin J; Candemark E; Levan K; Haraldsson B; Nyström J
    BMC Nephrol; 2016 Apr; 17():40. PubMed ID: 27044423
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sialylation of IgG inhibits the formation of galactose-deficient IgA1-containing immune complexes and protects mesangial cells from injury in IgA nephropathy.
    Liu Y; Li H; Yu H; Wang F; Jia J; Yan T
    BMC Nephrol; 2022 Jan; 23(1):25. PubMed ID: 35016642
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aberrant glycosylation of IgA1 and anti-glycan antibodies in IgA nephropathy: role of mucosal immune system.
    Novak J; Moldoveanu Z; Julian BA; Raska M; Wyatt RJ; Suzuki Y; Tomino Y; Gharavi AG; Mestecky J; Suzuki H
    Adv Otorhinolaryngol; 2011; 72():60-3. PubMed ID: 21865691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Paradigm shift in activity assessment of IgA nephropathy - optimizing the next generation of diagnostic and therapeutic maneuvers via glycan targeting.
    Suzuki Y; Suzuki H; Yasutake J; Tomino Y
    Expert Opin Biol Ther; 2015 Apr; 15(4):583-93. PubMed ID: 25604055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Both IgA nephropathy and alcoholic cirrhosis feature abnormally glycosylated IgA1 and soluble CD89-IgA and IgG-IgA complexes: common mechanisms for distinct diseases.
    Tissandié E; Morelle W; Berthelot L; Vrtovsnik F; Daugas E; Walker F; Lebrec D; Trawalé JM; Francoz C; Durand F; Moura IC; Paradis V; Moreau R; Monteiro RC
    Kidney Int; 2011 Dec; 80(12):1352-63. PubMed ID: 21866091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Binding capacity and pathophysiological effects of IgA1 from patients with IgA nephropathy on human glomerular mesangial cells.
    Wang Y; Zhao MH; Zhang YK; Li XM; Wang HY
    Clin Exp Immunol; 2004 Apr; 136(1):168-75. PubMed ID: 15030528
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transferrin receptor engagement by polymeric IgA1 induces receptor expression and mesangial cell proliferation: role in IgA nephropathy.
    Tamouza H; Vende F; Tiwari M; Arcos-Fajardo M; Vrtovsnik F; Benhamou M; Monteiro RC; Moura IC
    Contrib Nephrol; 2007; 157():144-7. PubMed ID: 17495453
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sparsentan ameliorates glomerular hypercellularity and inflammatory-gene networks induced by IgA1-IgG immune complexes in a mouse model of IgA nephropathy.
    Reily C; Moldoveanu Z; Pramparo T; Hall S; Huang ZQ; Rice T; Novak L; Komers R; Jenkinson CP; Novak J
    Am J Physiol Renal Physiol; 2024 May; 326(5):F862-F875. PubMed ID: 38511222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glomerular Immunodeposits of Patients with IgA Nephropathy Are Enriched for IgG Autoantibodies Specific for Galactose-Deficient IgA1.
    Rizk DV; Saha MK; Hall S; Novak L; Brown R; Huang ZQ; Fatima H; Julian BA; Novak J
    J Am Soc Nephrol; 2019 Oct; 30(10):2017-2026. PubMed ID: 31444275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. IgA nephropathy: characterization of IgG antibodies specific for galactose-deficient IgA1.
    Suzuki H; Moldoveanu Z; Hall S; Brown R; Julian BA; Wyatt RJ; Tomana M; Tomino Y; Novak J; Mestecky J
    Contrib Nephrol; 2007; 157():129-33. PubMed ID: 17495450
    [TBL] [Abstract][Full Text] [Related]  

  • 12. IgA nephropathy and Henoch-Schoenlein purpura nephritis: aberrant glycosylation of IgA1, formation of IgA1-containing immune complexes, and activation of mesangial cells.
    Novak J; Moldoveanu Z; Renfrow MB; Yanagihara T; Suzuki H; Raska M; Hall S; Brown R; Huang WQ; Goepfert A; Kilian M; Poulsen K; Tomana M; Wyatt RJ; Julian BA; Mestecky J
    Contrib Nephrol; 2007; 157():134-8. PubMed ID: 17495451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The IgA1 immune complex-mediated activation of the MAPK/ERK kinase pathway in mesangial cells is associated with glomerular damage in IgA nephropathy.
    Tamouza H; Chemouny JM; Raskova Kafkova L; Berthelot L; Flamant M; Demion M; Mesnard L; Paubelle E; Walker F; Julian BA; Tissandié E; Tiwari MK; Camara NO; Vrtovsnik F; Benhamou M; Novak J; Monteiro RC; Moura IC
    Kidney Int; 2012 Dec; 82(12):1284-96. PubMed ID: 22951891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of aberrant glycosylation of IgA1 molecules in the pathogenesis of IgA nephropathy.
    Mestecky J; Tomana M; Moldoveanu Z; Julian BA; Suzuki H; Matousovic K; Renfrow MB; Novak L; Wyatt RJ; Novak J
    Kidney Blood Press Res; 2008; 31(1):29-37. PubMed ID: 18182777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune characteristics of renal allograft donors with mesangial IgA deposition.
    Wang Z; Zhang X; Han W; Yu G; Ying Z; Xu X; Wang M; Zhou X; Lv J; Zhang H
    Int Immunopharmacol; 2021 Feb; 91():107282. PubMed ID: 33370682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Galactose-Deficient IgA1 B cells in the Circulation of IgA Nephropathy Patients Carry Preferentially Lambda Light Chains and Mucosal Homing Receptors.
    Zachova K; Jemelkova J; Kosztyu P; Ohyama Y; Takahashi K; Zadrazil J; Orsag J; Matousovic K; Galuszkova D; Petejova N; Mestecky J; Raska M
    J Am Soc Nephrol; 2022 May; 33(5):908-917. PubMed ID: 35115327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic effect of mesangial cell-induced CXCL1 and TGF-β1 in promoting podocyte loss in IgA nephropathy.
    Zhu L; Zhang Q; Shi S; Liu L; Lv J; Zhang H
    PLoS One; 2013; 8(8):e73425. PubMed ID: 24023680
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Integrin α1/β1 and α2/β1 as a receptor for IgA1 in human glomerular mesangial cells in IgA nephropathy.
    Kaneko Y; Otsuka T; Tsuchida Y; Gejyo F; Narita I
    Int Immunol; 2012 Apr; 24(4):219-32. PubMed ID: 22298882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneity.
    Suzuki H; Fan R; Zhang Z; Brown R; Hall S; Julian BA; Chatham WW; Suzuki Y; Wyatt RJ; Moldoveanu Z; Lee JY; Robinson J; Tomana M; Tomino Y; Mestecky J; Novak J
    J Clin Invest; 2009 Jun; 119(6):1668-77. PubMed ID: 19478457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recognition of galactose-deficient O-glycans in the hinge region of IgA1 by N-acetylgalactosamine-specific snail lectins: a comparative binding study.
    Gomes MM; Suzuki H; Brooks MT; Tomana M; Moldoveanu Z; Mestecky J; Julian BA; Novak J; Herr AB
    Biochemistry; 2010 Jul; 49(27):5671-82. PubMed ID: 20507092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.